{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:28:21Z","timestamp":1783484901067,"version":"3.55.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"DOI":"10.7759\/cureus.104583","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:32:05Z","timestamp":1772515925000},"source":"Crossref","is-referenced-by-count":1,"title":["Peroxisome Proliferator-Activated Receptors (PPARs) in Psoriasis: Metabolic Intersections, Molecular Mechanisms, and Potential Treatments"],"prefix":"10.7759","author":[{"given":"Venkata Bharat Kumar","family":"Pinnelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra Babu","family":"T","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashankar","family":"CA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Bhanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aga Ammar","family":"Murthuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Thipani Madhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilekha","family":"N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshy T","family":"Sam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Hyder","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"AS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkataramana","family":"Kandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Global report on psoriasis. (2016). Accessed. January 1, 2026: https:\/\/www.who.int\/publications\/i\/item\/9789241565189."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke WH","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015, 386:983-94. 10.1016\/S0140-6736(14)61909-7","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study","volume":"78","author":"Wan MT","year":"2018","unstructured":"Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018, 78:315-22.e1. 10.1016\/j.jaad.2017.10.050","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63379","article-title":"The association between psoriasis and atherosclerotic cardiovascular disease: a systematic review and meta-analysis of observational studies","volume":"16","author":"Osigwe PC","year":"2024","unstructured":"Osigwe PC, Agomoh CE, Osigwe IS, Akumiah FK. The association between psoriasis and atherosclerotic cardiovascular disease: a systematic review and meta-analysis of observational studies. Cureus. 2024, 16:e63379. 10.7759\/cureus.63379","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand JM","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006, 296:1735-41. 10.1001\/jama.296.14.1735","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with\u00a0psoriasis: JACC review topic of the week","volume":"77","author":"Garshick MS","year":"2021","unstructured":"Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with\u00a0psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021, 77:1670-80. 10.1016\/j.jacc.2021.02.009","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.037","article-title":"All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis","volume":"80","author":"Dhana A","year":"2019","unstructured":"Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2019, 80:1332-43. 10.1016\/j.jaad.2018.12.037","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events","volume":"77","author":"Egeberg A","year":"2017","unstructured":"Egeberg A, Skov L, Joshi AA, et al.. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017, 77:650-6.e3. 10.1016\/j.jaad.2017.06.028","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines","volume":"9","author":"Fitch E","year":"2007","unstructured":"Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007, 9:461-7. 10.1007\/s11926-007-0075-1","journal-title":"Curr Rheumatol Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.06.068","article-title":"Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis","volume":"224","author":"Mehta NN","year":"2012","unstructured":"Mehta NN, Li R, Krishnamoorthy P, et al.. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012, 224:218-21. 10.1016\/j.atherosclerosis.2012.06.068","journal-title":"Atherosclerosis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke WH","year":"2011","unstructured":"Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011, 20:303-7. 10.1111\/j.1600-0625.2011.01261.x","journal-title":"Exp Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes JE","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017, 140:645-53. 10.1016\/j.jaci.2017.07.004","journal-title":"J Allergy Clin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths CE","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007, 370:263-71. 10.1016\/S0140-6736(07)61128-3","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23 Suppl 2","author":"Pathirana D","year":"2009","unstructured":"Pathirana D, Ormerod AD, Saiag P, et al.. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009, 23 Suppl 2:1-70. 10.1111\/j.1468-3083.2009.03389.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger JG","year":"2012","unstructured":"Krueger JG, Fretzin S, Su\u00e1rez-Fari\u00f1as M, et al.. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012, 130:145-54.e9. 10.1016\/j.jaci.2012.04.024","journal-title":"J Allergy Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon KB","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, et al.. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015, 373:136-44. 10.1056\/NEJMoa1501646","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00964-6","article-title":"Long-term safety and efficacy of risankizumab to treat moderate-to-severe plaque psoriasis: final LIMMitless phase 3, open-label extension trial results","volume":"26","author":"Papp KA","year":"2025","unstructured":"Papp KA, Lebwohl MG, Puig L, et al.. Long-term safety and efficacy of risankizumab to treat moderate-to-severe plaque psoriasis: final LIMMitless phase 3, open-label extension trial results. Am J Clin Dermatol. 2025, 26:829-41. 10.1007\/s40257-025-00964-6","journal-title":"Am J Clin Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.02.003","article-title":"Bioactive lipid mediator profiles in human psoriasis skin and blood","volume":"138","author":"Sorokin AV","year":"2018","unstructured":"Sorokin AV, Domenichiello AF, Dey AK, et al.. Bioactive lipid mediator profiles in human psoriasis skin and blood. J Invest Dermatol. 2018, 138:1518-28. 10.1016\/j.jid.2018.02.003","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.10.031","article-title":"IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response","volume":"123","author":"Eyerich K","year":"2009","unstructured":"Eyerich K, Pennino D, Scarponi C, et al.. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol. 2009, 123:59-66.e4. 10.1016\/j.jaci.2008.10.031","journal-title":"J Allergy Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong AW","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012, 2:e54. 10.1038\/nutd.2012.26","journal-title":"Nutr Diabetes"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2026.01.003","article-title":"Reprogramming immunity at the metabolic-epidermal interface in obesity-associated psoriasis","volume":"88","author":"Jang J","year":"2026","unstructured":"Jang J, Park M, Kim HJ, Jung Y. Reprogramming immunity at the metabolic-epidermal interface in obesity-associated psoriasis. Cytokine Growth Factor Rev. 2026, 88:32-46. 10.1016\/j.cytogfr.2026.01.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/genes11101155","article-title":"Transcriptome profiling analyses in psoriasis: a dynamic contribution of keratinocytes to the pathogenesis","volume":"11","author":"Rioux G","year":"2020","unstructured":"Rioux G, Ridha Z, Simard M, Turgeon F, Gu\u00e9rin SL, Pouliot R. Transcriptome profiling analyses in psoriasis: a dynamic contribution of keratinocytes to the pathogenesis. Genes (Basel). 2020, 11:1155. 10.3390\/genes11101155","journal-title":"Genes (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82164","article-title":"Lipid abnormalities and electrocardiographic changes in patients with psoriasis in a tertiary care hospital","volume":"17","author":"Rajendran A","year":"2025","unstructured":"Rajendran A, Harikumar MV, Swaminathan A. Lipid abnormalities and electrocardiographic changes in patients with psoriasis in a tertiary care hospital. Cureus. 2025, 17:e82164. 10.7759\/cureus.82164","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/70.4.566","article-title":"Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors","volume":"70","author":"Clarke SD","year":"1999","unstructured":"Clarke SD, Thuillier P, Baillie RA, Sha X. Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors. Am J Clin Nutr. 1999, 70:566-71. 10.1093\/ajcn\/70.4.566","journal-title":"Am J Clin Nutr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nm1025","article-title":"PPARs and the complex journey to obesity","volume":"10","author":"Evans RM","year":"2004","unstructured":"Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004, 10:355-61. 10.1038\/nm1025","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"Michalik L","year":"2006","unstructured":"Michalik L, Auwerx J, Berger JP, et al.. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006, 58:726-41. 10.1124\/pr.58.4.5","journal-title":"Pharmacol Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli W","year":"2012","unstructured":"Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012, 23:351-63. 10.1016\/j.tem.2012.05.001","journal-title":"Trends Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jidsymp.5650007","article-title":"Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis","volume":"11","author":"Icre G","year":"2006","unstructured":"Icre G, Wahli W, Michalik L. Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis. J Investig Dermatol Symp Proc. 2006, 11:30-5. 10.1038\/sj.jidsymp.5650007","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.9.4318","article-title":"Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma","volume":"94","author":"Kliewer SA","year":"1997","unstructured":"Kliewer SA, Sundseth SS, Jones SA, et al.. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997, 94:4318-23. 10.1073\/pnas.94.9.4318","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.036","article-title":"Identification of a physiologically relevant endogenous ligand for PPARalpha in liver","volume":"138","author":"Chakravarthy MV","year":"2009","unstructured":"Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, Semenkovich CF. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 2009, 138:476-88. 10.1016\/j.cell.2009.05.036","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/nri2748","article-title":"Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells","volume":"10","author":"Glass CK","year":"2010","unstructured":"Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 2010, 10:365-76. 10.1038\/nri2748","journal-title":"Nat Rev Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2007.02.013","article-title":"PPARs and molecular mechanisms of transrepression","volume":"1771","author":"Ricote M","year":"2007","unstructured":"Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta. 2007, 1771:926-35. 10.1016\/j.bbalip.2007.02.013","journal-title":"Biochim Biophys Acta"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_114_18","article-title":"Peroxisome proliferator-activated receptor-\u03b3 gene polymorphism in psoriasis and its relation to obesity, metabolic syndrome, and narrowband ultraviolet B response: a case-control study in Egyptian patients","volume":"64","author":"Seleit I","year":"2019","unstructured":"Seleit I, Bakry OA, Abd El Gayed E, Ghanem M. Peroxisome proliferator-activated receptor-\u03b3 gene polymorphism in psoriasis and its relation to obesity, metabolic syndrome, and narrowband ultraviolet B response: a case-control study in Egyptian patients. Indian J Dermatol. 2019, 64:192-200. 10.4103\/ijd.IJD_114_18","journal-title":"Indian J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang C","year":"1998","unstructured":"Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998, 391:82-6. 10.1038\/34184","journal-title":"Nature"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu067","article-title":"Modulation of aryl hydrocarbon receptor (AHR)-dependent signaling by peroxisome proliferator-activated receptor \u03b2\/\u03b4 (PPAR\u03b2\/\u03b4) in keratinocytes","volume":"35","author":"Borland MG","year":"2014","unstructured":"Borland MG, Krishnan P, Lee C, et al.. Modulation of aryl hydrocarbon receptor (AHR)-dependent signaling by peroxisome proliferator-activated receptor \u03b2\/\u03b4 (PPAR\u03b2\/\u03b4) in keratinocytes. Carcinogenesis. 2014, 35:1602-12. 10.1093\/carcin\/bgu067","journal-title":"Carcinogenesis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6529057","article-title":"The model of PPAR\u03b3-downregulated signaling in psoriasis","volume":"2020","author":"Sobolev V","year":"2020","unstructured":"Sobolev V, Nesterova A, Soboleva A, et al.. The model of PPAR\u03b3-downregulated signaling in psoriasis. PPAR Res. 2020, 2020:6529057. 10.1155\/2020\/6529057","journal-title":"PPAR Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2004.08.004","article-title":"Dyslipidemia and inflammation: an evolutionary conserved mechanism","volume":"24","author":"Esteve E","year":"2005","unstructured":"Esteve E, Ricart W, Fern\u00e1ndez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005, 24:16-31. 10.1016\/j.clnu.2004.08.004","journal-title":"Clin Nutr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147354","article-title":"PPARdelta in affected atopic dermatitis and psoriasis: a possible role in metabolic reprograming","volume":"22","author":"Blunder S","year":"2021","unstructured":"Blunder S, Pavel P, Minzaghi D, Dubrac S. PPARdelta in affected atopic dermatitis and psoriasis: a possible role in metabolic reprograming. Int J Mol Sci. 2021, 22:7354. 10.3390\/ijms22147354","journal-title":"Int J Mol Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.08.027","article-title":"A PPAR\u03b4-selective antagonist ameliorates IMQ-induced psoriasis-like inflammation in mice","volume":"40","author":"Wang X","year":"2016","unstructured":"Wang X, Hao Y, Wang X, Wang L, Chen Y, Sun J, Hu J. A PPAR\u03b4-selective antagonist ameliorates IMQ-induced psoriasis-like inflammation in mice. Int Immunopharmacol. 2016, 40:73-8. 10.1016\/j.intimp.2016.08.027","journal-title":"Int Immunopharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12329907","article-title":"Modeling acne in vitro","volume":"106","author":"Guy R","year":"1996","unstructured":"Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol. 1996, 106:176-82. 10.1111\/1523-1747.ep12329907","journal-title":"J Invest Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1590\/bjpt-rbf.2014.0141","article-title":"Wound healing treatment by high frequency ultrasound, microcurrent, and combined therapy modifies the immune response in rats","volume":"20","author":"Korelo RI","year":"2016","unstructured":"Korelo RI, Kryczyk M, Garcia C, Naliwaiko K, Fernandes LC. Wound healing treatment by high frequency ultrasound, microcurrent, and combined therapy modifies the immune response in rats. Braz J Phys Ther. 2016, 20:133-41. 10.1590\/bjpt-rbf.2014.0141","journal-title":"Braz J Phys Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/000155500459240","article-title":"Expression of peroxisome proliferator activated receptors (PPARs) in human hair follicles and PPAR alpha involvement in hair growth","volume":"80","author":"Billoni N","year":"2000","unstructured":"Billoni N, Buan B, Gautier B, Collin C, Gaillard O, Mah\u00e9 YF, Bernard BA. Expression of peroxisome proliferator activated receptors (PPARs) in human hair follicles and PPAR alpha involvement in hair growth. Acta Derm Venereol. 2000, 80:329-34. 10.1080\/000155500459240","journal-title":"Acta Derm Venereol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2010.10.024","article-title":"Gene expression in skin and lymphoblastoid cells: refined statistical method reveals extensive overlap in cis-eQTL signals","volume":"87","author":"Ding J","year":"2010","unstructured":"Ding J, Gudjonsson JE, Liang L, et al.. Gene expression in skin and lymphoblastoid cells: refined statistical method reveals extensive overlap in cis-eQTL signals. Am J Hum Genet. 2010, 87:779-89. 10.1016\/j.ajhg.2010.10.024","journal-title":"Am J Hum Genet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/med.1006","article-title":"Cyclopentenone prostaglandins: new insights on biological activities and cellular targets","volume":"21","author":"Straus DS","year":"2001","unstructured":"Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev. 2001, 21:185-210. 10.1002\/med.1006","journal-title":"Med Res Rev"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168603","article-title":"Analysis of PPAR\u03b3 signaling activity in psoriasis","volume":"22","author":"Sobolev V","year":"2021","unstructured":"Sobolev V, Nesterova A, Soboleva A, et al.. Analysis of PPAR\u03b3 signaling activity in psoriasis. Int J Mol Sci. 2021, 22:8603. 10.3390\/ijms22168603","journal-title":"Int J Mol Sci"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante M","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012, 149:274-93. 10.1016\/j.cell.2012.03.017","journal-title":"Cell"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.832732","article-title":"The role of peroxisome proliferator-activated receptors in kidney diseases","volume":"13","author":"Gao J","year":"2022","unstructured":"Gao J, Gu Z. The role of peroxisome proliferator-activated receptors in kidney diseases. Front Pharmacol. 2022, 13:832732. 10.3389\/fphar.2022.832732","journal-title":"Front Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2021.11.005","article-title":"Comprehensive-targeted lipidomic analysis in Niemann-Pick C disease","volume":"134","author":"Boenzi S","year":"2021","unstructured":"Boenzi S, Catesini G, Sacchetti E, Tagliaferri F, Dionisi-Vici C, Deodato F. Comprehensive-targeted lipidomic analysis in Niemann-Pick C disease. Mol Genet Metab. 2021, 134:337-43. 10.1016\/j.ymgme.2021.11.005","journal-title":"Mol Genet Metab"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/nature03988","article-title":"A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma","volume":"437","author":"Pascual G","year":"2005","unstructured":"Pascual G, Fong AL, Ogawa S, et al.. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005, 437:759-63. 10.1038\/nature03988","journal-title":"Nature"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism","volume":"2015","author":"Kroker AJ","year":"2015","unstructured":"Kroker AJ, Bruning JB. Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism. PPAR Res. 2015, 2015:816856. 10.1155\/2015\/816856","journal-title":"PPAR Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin AC","year":"2012","unstructured":"Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012, 13:213-24. 10.1038\/nrm3312","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3126\/jnba.v6i1.76912","article-title":"Antioxidant and antidiabetic potential of extracts from selected species of Smilax L","volume":"6","author":"Adhikari S","year":"2025","unstructured":"Adhikari S, Pant DR, Joshi GP. Antioxidant and antidiabetic potential of extracts from selected species of Smilax L. Nepal J Biotechnol. 2025, 6:1-8. 10.3126\/jnba.v6i1.76912","journal-title":"Nepal J Biotechnol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205068","article-title":"PPAR\u03b3 and cognitive performance","volume":"20","author":"d'Angelo M","year":"2019","unstructured":"d'Angelo M, Castelli V, Catanesi M, et al.. PPAR\u03b3 and cognitive performance. Int J Mol Sci. 2019, 20:5068. 10.3390\/ijms20205068","journal-title":"Int J Mol Sci"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes MA","year":"2013","unstructured":"Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013, 34:174-81. 10.1016\/j.it.2012.11.005","journal-title":"Trends Immunol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155357","article-title":"Synergistic induction of IL-23 by TNF\u03b1, IL-17A, and EGF in keratinocytes","volume":"138","author":"Ehst B","year":"2021","unstructured":"Ehst B, Wang Z, Leitenberger J, et al.. Synergistic induction of IL-23 by TNF\u03b1, IL-17A, and EGF in keratinocytes. Cytokine. 2021, 138:155357. 10.1016\/j.cyto.2020.155357","journal-title":"Cytokine"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082771","article-title":"The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity","volume":"206","author":"Klotz L","year":"2009","unstructured":"Klotz L, Burgdorf S, Dani I, et al.. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med. 2009, 206:2079-89. 10.1084\/jem.20082771","journal-title":"J Exp Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00577","article-title":"Antagonizing retinoic acid-related-orphan receptor gamma activity blocks the T helper 17\/interleukin-17 pathway leading to attenuated pro-inflammatory human keratinocyte and skin responses","volume":"10","author":"Ecoeur F","year":"2019","unstructured":"Ecoeur F, Weiss J, Kaupmann K, Hintermann S, Orain D, Guntermann C. Antagonizing retinoic acid-related-orphan receptor gamma activity blocks the T helper 17\/interleukin-17 pathway leading to attenuated pro-inflammatory human keratinocyte and skin responses. Front Immunol. 2019, 10:577. 10.3389\/fimmu.2019.00577","journal-title":"Front Immunol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2337\/db08-1637","article-title":"Butyrate improves insulin sensitivity and increases energy expenditure in mice","volume":"58","author":"Gao Z","year":"2009","unstructured":"Gao Z, Yin J, Zhang J, et al.. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009, 58:1509-17. 10.2337\/db08-1637","journal-title":"Diabetes"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019658108","article-title":"Epidermal ablation of Dlx3 is linked to IL-17-associated skin inflammation","volume":"108","author":"Hwang J","year":"2011","unstructured":"Hwang J, Kita R, Kwon HS, Choi EH, Lee SH, Udey MC, Morasso MI. Epidermal ablation of Dlx3 is linked to IL-17-associated skin inflammation. Proc Natl Acad Sci U S A. 2011, 108:11566-71. 10.1073\/pnas.1019658108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.10.043","article-title":"Peroxisome proliferator-activated receptor \u03b3-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC\/Tnd mice","volume":"127","author":"Jung K","year":"2011","unstructured":"Jung K, Tanaka A, Fujita H, et al.. Peroxisome proliferator-activated receptor \u03b3-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC\/Tnd mice. J Allergy Clin Immunol. 2011, 127:420-9.e1-6. 10.1016\/j.jaci.2010.10.043","journal-title":"J Allergy Clin Immunol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2018.11.002","article-title":"Ascorbic acid derivative DDH-1 ameliorates psoriasis-like skin lesions in mice by suppressing inflammatory cytokine expression","volume":"138","author":"Kitahata K","year":"2018","unstructured":"Kitahata K, Matsuo K, Hara Y, Naganuma T, Oiso N, Kawada A, Nakayama T. Ascorbic acid derivative DDH-1 ameliorates psoriasis-like skin lesions in mice by suppressing inflammatory cytokine expression. J Pharmacol Sci. 2018, 138:284-8. 10.1016\/j.jphs.2018.11.002","journal-title":"J Pharmacol Sci"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20162069","article-title":"PPAR\u03b3 in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation","volume":"214","author":"Nobs SP","year":"2017","unstructured":"Nobs SP, Natali S, Pohlmeier L, et al.. PPAR\u03b3 in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation. J Exp Med. 2017, 214:3015-35. 10.1084\/jem.20162069","journal-title":"J Exp Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/519724","article-title":"PPAR\u03b3 agonists in adaptive immunity: what do immune disorders and their models have to tell us?","volume":"2013","author":"da Rocha Junior LF","year":"2013","unstructured":"da Rocha Junior LF, Dantas AT, Duarte AL, de Melo Rego MJ, Pitta Ida R, Pitta MG. PPAR\u03b3 agonists in adaptive immunity: what do immune disorders and their models have to tell us?. PPAR Res. 2013, 2013:519724. 10.1155\/2013\/519724","journal-title":"PPAR Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali DA","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008, 8:523-32. 10.1038\/nri2343","journal-title":"Nat Rev Immunol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3109\/08820139.2014.917095","article-title":"Estrogen inhibits LPS-induced IL-6 production in macrophages partially via the nongenomic pathway","volume":"43","author":"Liu L","year":"2014","unstructured":"Liu L, Zhao Y, Xie K, Sun X, Jiang L, Gao Y, Wang Z. Estrogen inhibits LPS-induced IL-6 production in macrophages partially via the nongenomic pathway. Immunol Invest. 2014, 43:693-704. 10.3109\/08820139.2014.917095","journal-title":"Immunol Invest"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1999.00538.x","article-title":"Animal models of psoriasis - what can we learn from them?","volume":"112","author":"Sch\u00f6n MP","year":"1999","unstructured":"Sch\u00f6n MP. Animal models of psoriasis - what can we learn from them?. J Invest Dermatol. 1999, 112:405-10. 10.1046\/j.1523-1747.1999.00538.x","journal-title":"J Invest Dermatol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou X","year":"2022","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022, 13:81. 10.1038\/s41419-022-04523-3","journal-title":"Cell Death Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan AG","year":"2008","unstructured":"Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008, 371:569-78. 10.1016\/S0140-6736(08)60269-X","journal-title":"Lancet"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.11.003","article-title":"Neuroinflammation and neurodegeneration in overnutrition-induced diseases","volume":"24","author":"Cai D","year":"2013","unstructured":"Cai D. Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol Metab. 2013, 24:40-7. 10.1016\/j.tem.2012.11.003","journal-title":"Trends Endocrinol Metab"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2570","article-title":"Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity","volume":"14","author":"Kidani Y","year":"2013","unstructured":"Kidani Y, Elsaesser H, Hock MB, et al.. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol. 2013, 14:489-99. 10.1038\/ni.2570","journal-title":"Nat Immunol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/med.21970","article-title":"Molecular mechanisms and therapeutic perspectives of peroxisome proliferator-activated receptor \u03b1 agonists in cardiovascular health and disease","volume":"43","author":"Pu Y","year":"2023","unstructured":"Pu Y, Cheng CK, Zhang H, Luo JY, Wang L, Tomlinson B, Huang Y. Molecular mechanisms and therapeutic perspectives of peroxisome proliferator-activated receptor \u03b1 agonists in cardiovascular health and disease. Med Res Rev. 2023, 43:2086-114. 10.1002\/med.21970","journal-title":"Med Res Rev"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1254","article-title":"Peroxisome-proliferator-activated receptors and cancers: complex stories","volume":"4","author":"Michalik L","year":"2004","unstructured":"Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004, 4:61-70. 10.1038\/nrc1254","journal-title":"Nat Rev Cancer"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-007-0060-9","article-title":"The skin barrier as an innate immune element","volume":"29","author":"Elias PM","year":"2007","unstructured":"Elias PM. The skin barrier as an innate immune element. Semin Immunopathol. 2007, 29:3-14. 10.1007\/s00281-007-0060-9","journal-title":"Semin Immunopathol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12658","article-title":"Keratinocyte differentiation and upregulation of ceramide synthesis induced by an oat lipid extract via the activation of PPAR pathways","volume":"24","author":"Chon SH","year":"2015","unstructured":"Chon SH, Tannahill R, Yao X, Southall MD, Pappas A. Keratinocyte differentiation and upregulation of ceramide synthesis induced by an oat lipid extract via the activation of PPAR pathways. Exp Dermatol. 2015, 24:290-5. 10.1111\/exd.12658","journal-title":"Exp Dermatol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3390\/genes12050645","article-title":"The role of lipid sensing nuclear receptors (PPARs and LXR) and metabolic lipases in obesity, diabetes and NAFLD","volume":"12","author":"Dixon ED","year":"2021","unstructured":"Dixon ED, Nardo AD, Claudel T, Trauner M. The role of lipid sensing nuclear receptors (PPARs and LXR) and metabolic lipases in obesity, diabetes and NAFLD. Genes (Basel). 2021, 12:645. 10.3390\/genes12050645","journal-title":"Genes (Basel)"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.03.006","article-title":"High-throughput transcriptome and pathogenesis analysis of clinical psoriasis","volume":"98","author":"Yu Z","year":"2020","unstructured":"Yu Z, Gong Y, Cui L, et al.. High-throughput transcriptome and pathogenesis analysis of clinical psoriasis. J Dermatol Sci. 2020, 98:109-18. 10.1016\/j.jdermsci.2020.03.006","journal-title":"J Dermatol Sci"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202417049","article-title":"Reprogramming of fatty acid metabolism via PPAR\u03b1-orchestrated FADS2 in keratinocytes modulates skin inflammation in psoriasis","volume":"12","author":"Cai J","year":"2025","unstructured":"Cai J, Zhou X, Zhuang Y, et al.. Reprogramming of fatty acid metabolism via PPAR\u03b1-orchestrated FADS2 in keratinocytes modulates skin inflammation in psoriasis. Adv Sci (Weinh). 2025, 12:e17049. 10.1002\/advs.202417049","journal-title":"Adv Sci (Weinh)"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-194","article-title":"Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis","volume":"11","author":"Mehta NN","year":"2013","unstructured":"Mehta NN, Li K, Szapary P, Krueger J, Brodmerkel C. Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Transl Med. 2013, 11:194. 10.1186\/1479-5876-11-194","journal-title":"J Transl Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03726-1","article-title":"Immune responses and therapeutic options in psoriasis","volume":"78","author":"Afonina IS","year":"2021","unstructured":"Afonina IS, Van Nuffel E, Beyaert R. Immune responses and therapeutic options in psoriasis. Cell Mol Life Sci. 2021, 78:2709-27. 10.1007\/s00018-020-03726-1","journal-title":"Cell Mol Life Sci"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/s0923-1811(99)00042-0","article-title":"Psoriasis and the arachidonic acid cascade","volume":"21","author":"Ikai K","year":"1999","unstructured":"Ikai K. Psoriasis and the arachidonic acid cascade. J Dermatol Sci. 1999, 21:135-46. 10.1016\/s0923-1811(99)00042-0","journal-title":"J Dermatol Sci"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12470233","article-title":"Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin?","volume":"96","author":"Imokawa G","year":"1991","unstructured":"Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin?. J Invest Dermatol. 1991, 96:523-6. 10.1111\/1523-1747.ep12470233","journal-title":"J Invest Dermatol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425","author":"Fu J","year":"2003","unstructured":"Fu J, Gaetani S, Oveisi F, et al.. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003, 425:90-3. 10.1038\/nature01921","journal-title":"Nature"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1101\/gad.844900","article-title":"Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta","volume":"14","author":"Repa JJ","year":"2000","unstructured":"Repa JJ, Liang G, Ou J, et al.. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-30. 10.1101\/gad.844900","journal-title":"Genes Dev"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)33401-5","article-title":"Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol","volume":"40","author":"Ntambi JM","year":"1999","unstructured":"Ntambi JM. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res. 1999, 40:1549-58. 10.1016\/S0022-2275(20)33401-5","journal-title":"J Lipid Res"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2010.05.012","article-title":"Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis","volume":"12","author":"Ellis JM","year":"2010","unstructured":"Ellis JM, Li LO, Wu PC, et al.. Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab. 2010, 12:53-64. 10.1016\/j.cmet.2010.05.012","journal-title":"Cell Metab"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.4161\/derm.3.2.15136","article-title":"The roles of ABCA12 in keratinocyte differentiation and lipid barrier formation in the epidermis","volume":"3","author":"Akiyama M","year":"2011","unstructured":"Akiyama M. The roles of ABCA12 in keratinocyte differentiation and lipid barrier formation in the epidermis. Dermatoendocrinol. 2011, 3:107-12. 10.4161\/derm.3.2.15136","journal-title":"Dermatoendocrinol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb00222.x","article-title":"Barrier function regulates epidermal lipid and DNA synthesis","volume":"128","author":"Proksch E","year":"1993","unstructured":"Proksch E, Holleran WM, Menon GK, Elias PM, Feingold KR. Barrier function regulates epidermal lipid and DNA synthesis. Br J Dermatol. 1993, 128:473-82. 10.1111\/j.1365-2133.1993.tb00222.x","journal-title":"Br J Dermatol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1080\/00015550510030104","article-title":"Peroxisome proliferator-activated receptors and their relevance to dermatology","volume":"85","author":"Friedmann PS","year":"2005","unstructured":"Friedmann PS, Cooper HL, Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm Venereol. 2005, 85:194-202. 10.1080\/00015550510030104","journal-title":"Acta Derm Venereol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13040493","article-title":"Effects of hypolipidemic drugs on psoriasis","volume":"13","author":"Matwiejuk M","year":"2023","unstructured":"Matwiejuk M, Mysliwiec H, Jakubowicz-Zalewska O, Chabowski A, Flisiak I. Effects of hypolipidemic drugs on psoriasis. Metabolites. 2023, 13:493. 10.3390\/metabo13040493","journal-title":"Metabolites"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700943","article-title":"PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor","volume":"128","author":"Romanowska M","year":"2008","unstructured":"Romanowska M, al Yacoub N, Seidel H, et al.. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol. 2008, 128:110-24. 10.1038\/sj.jid.5700943","journal-title":"J Invest Dermatol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19325","article-title":"Advancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches","volume":"13","author":"Chakith M R S","year":"2025","unstructured":"Chakith M R S, Pradeep S, Gangadhar M, et al.. Advancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches. PeerJ. 2025, 13:e19325. 10.7717\/peerj.19325","journal-title":"PeerJ"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2018.07.016","article-title":"Heparin-binding epidermal growth factor-like growth factor as a critical mediator of tissue repair and regeneration","volume":"188","author":"Dao DT","year":"2018","unstructured":"Dao DT, Anez-Bustillos L, Adam RM, Puder M, Bielenberg DR. Heparin-binding epidermal growth factor-like growth factor as a critical mediator of tissue repair and regeneration. Am J Pathol. 2018, 188:2446-56. 10.1016\/j.ajpath.2018.07.016","journal-title":"Am J Pathol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251810015","article-title":"PPAR\u03b2\/\u03b4 agonist GW0742 modulates microglial and astroglial gene expression in a rat model of temporal lobe epilepsy","volume":"25","author":"Zubareva OE","year":"2024","unstructured":"Zubareva OE, Kharisova AR, Roginskaya AI, et al.. PPAR\u03b2\/\u03b4 agonist GW0742 modulates microglial and astroglial gene expression in a rat model of temporal lobe epilepsy. Int J Mol Sci. 2024, 25:10015. 10.3390\/ijms251810015","journal-title":"Int J Mol Sci"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29215189","article-title":"Selective PPAR\u03b4 agonist GW501516 protects against LPS-induced macrophage inflammation and acute liver failure in mice via suppressing inflammatory mediators","volume":"29","author":"Lim HJ","year":"2024","unstructured":"Lim HJ, Kwak HJ. Selective PPAR\u03b4 agonist GW501516 protects against LPS-induced macrophage inflammation and acute liver failure in mice via suppressing inflammatory mediators. Molecules. 2024, 29:5189. 10.3390\/molecules29215189","journal-title":"Molecules"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K","volume":"163","author":"Abuabara K","year":"2010","unstructured":"Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010, 163:586-92. 10.1111\/j.1365-2133.2010.09941.x","journal-title":"Br J Dermatol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities","volume":"11","author":"Menter A","year":"2021","unstructured":"Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG. Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb). 2021, 11:385-400. 10.1007\/s13555-021-00483-2","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111511","article-title":"Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Campanati A","year":"2021","unstructured":"Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines. 2021, 9:1511. 10.3390\/biomedicines9111511","journal-title":"Biomedicines"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3390\/ph18101527","article-title":"Adipokines at the metabolic-brain interface: therapeutic modulation by antidiabetic agents and natural compounds in Alzheimer's disease","volume":"18","author":"Ormazabal P","year":"2025","unstructured":"Ormazabal P, Bast\u00edas-P\u00e9rez M, Inestrosa NC, Cisternas P. Adipokines at the metabolic-brain interface: therapeutic modulation by antidiabetic agents and natural compounds in Alzheimer's disease. Pharmaceuticals (Basel). 2025, 18:1527. 10.3390\/ph18101527","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176401","article-title":"The role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis","volume":"21","author":"Tsukazaki H","year":"2020","unstructured":"Tsukazaki H, Kaito T. The role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis. Int J Mol Sci. 2020, 21:6401. 10.3390\/ijms21176401","journal-title":"Int J Mol Sci"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6090081","article-title":"IL-23 and Th17 disease in inflammatory arthritis","volume":"6","author":"Yago T","year":"2017","unstructured":"Yago T, Nanke Y, Kawamoto M, Kobashigawa T, Yamanaka H, Kotake S. IL-23 and Th17 disease in inflammatory arthritis. J Clin Med. 2017, 6:81. 10.3390\/jcm6090081","journal-title":"J Clin Med"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2018.10.008","article-title":"Risk of myocardial infarction in patients with psoriasis: a cross-sectional patient-population study in a Japanese hospital","volume":"73","author":"Shiba M","year":"2019","unstructured":"Shiba M, Kato T, Izumi T, Miyamoto S, Nakane E, Haruna T, Inoko M. Risk of myocardial infarction in patients with psoriasis: a cross-sectional patient-population study in a Japanese hospital. J Cardiol. 2019, 73:276-9. 10.1016\/j.jjcc.2018.10.008","journal-title":"J Cardiol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.3390\/life13101947","article-title":"Update on obesity in psoriasis patients","volume":"13","author":"Vata D","year":"2023","unstructured":"Vata D, Tarcau BM, Popescu IA, et al.. Update on obesity in psoriasis patients. Life (Basel). 2023, 13:1947. 10.3390\/life13101947","journal-title":"Life (Basel)"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711060","article-title":"Metabolic syndrome and psoriasis: mechanisms and future directions","volume":"12","author":"Hao Y","year":"2021","unstructured":"Hao Y, Zhu YJ, Zou S, et al.. Metabolic syndrome and psoriasis: mechanisms and future directions. Front Immunol. 2021, 12:711060. 10.3389\/fimmu.2021.711060","journal-title":"Front Immunol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216095","article-title":"Inflammation and psoriasis: a comprehensive review","volume":"24","author":"Man AM","year":"2023","unstructured":"Man AM, Or\u0103san MS, Hoteiuc OA, Ol\u0103nescu-Vaida-Voevod MC, Mocan T. Inflammation and psoriasis: a comprehensive review. Int J Mol Sci. 2023, 24:16095. 10.3390\/ijms242216095","journal-title":"Int J Mol Sci"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil GS","year":"2006","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006, 444:860-7. 10.1038\/nature05485","journal-title":"Nature"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26498","article-title":"MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity","volume":"116","author":"Kanda H","year":"2006","unstructured":"Kanda H, Tateya S, Tamori Y, et al.. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006, 116:1494-505. 10.1172\/JCI26498","journal-title":"J Clin Invest"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28898","article-title":"TLR4 links innate immunity and fatty acid-induced insulin resistance","volume":"116","author":"Shi H","year":"2006","unstructured":"Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006, 116:3015-25. 10.1172\/JCI28898","journal-title":"J Clin Invest"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021909-135846","article-title":"Macrophages, inflammation, and insulin resistance","volume":"72","author":"Olefsky JM","year":"2010","unstructured":"Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010, 72:219-46. 10.1146\/annurev-physiol-021909-135846","journal-title":"Annu Rev Physiol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjw014","article-title":"Adiponectin signaling and function in insulin target tissues","volume":"8","author":"Ruan H","year":"2016","unstructured":"Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol. 2016, 8:101-9. 10.1093\/jmcb\/mjw014","journal-title":"J Mol Cell Biol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1038\/31701","article-title":"Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators","volume":"393","author":"Staels B","year":"1998","unstructured":"Staels B, Koenig W, Habib A, et al.. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998, 393:790-3. 10.1038\/31701","journal-title":"Nature"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.03.008","article-title":"Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease","volume":"205","author":"Fruchart JC","year":"2009","unstructured":"Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009, 205:1-8. 10.1016\/j.atherosclerosis.2009.03.008","journal-title":"Atherosclerosis"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189775","article-title":"The regulatory roles of PPARs in skeletal muscle fuel metabolism and inflammation: impact of PPAR agonism on muscle in chronic disease, contraction and sepsis","volume":"22","author":"Crossland H","year":"2021","unstructured":"Crossland H, Constantin-Teodosiu D, Greenhaff PL. The regulatory roles of PPARs in skeletal muscle fuel metabolism and inflammation: impact of PPAR agonism on muscle in chronic disease, contraction and sepsis. Int J Mol Sci. 2021, 22:9775. 10.3390\/ijms22189775","journal-title":"Int J Mol Sci"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0306981100","article-title":"Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome","volume":"100","author":"Tanaka T","year":"2003","unstructured":"Tanaka T, Yamamoto J, Iwasaki S, et al.. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A. 2003, 100:15924-9. 10.1073\/pnas.0306981100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S342911","article-title":"Non-alcoholic fatty liver disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies","volume":"11","author":"Balak DM","year":"2021","unstructured":"Balak DM, Piaserico S, Kasujee I. Non-alcoholic fatty liver disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies. Psoriasis (Auckl). 2021, 11:151-68. 10.2147\/PTT.S342911","journal-title":"Psoriasis (Auckl)"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0297","article-title":"Psoriasis and the metabolic syndrome","volume":"87","author":"Cohen AD","year":"2007","unstructured":"Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, Vardy DA. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007, 87:506-9. 10.2340\/00015555-0297","journal-title":"Acta Derm Venereol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Sch\u00f6n MP","year":"2005","unstructured":"Sch\u00f6n MP, Boehncke WH. Psoriasis. N Engl J Med. 2005, 352:1899-912. 10.1056\/NEJMra041320","journal-title":"N Engl J Med"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152165","article-title":"Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review","volume":"59","author":"Torosian K","year":"2023","unstructured":"Torosian K, Lal E, Kavanaugh A, Loomba R, Ajmera V, Guma M. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Semin Arthritis Rheum. 2023, 59:152165. 10.1016\/j.semarthrit.2023.152165","journal-title":"Semin Arthritis Rheum"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S524893","article-title":"Therapeutic targeting of PPAR\u03b3 in nonalcoholic fatty liver disease: efficacy, safety, and drug development","volume":"19","author":"Zhou Z","year":"2025","unstructured":"Zhou Z, Jin R, Gu Y, Ji Y, Lou Y, Wu J. Therapeutic targeting of PPAR\u03b3 in nonalcoholic fatty liver disease: efficacy, safety, and drug development. Drug Des Devel Ther. 2025, 19:7293-319. 10.2147\/DDDT.S524893","journal-title":"Drug Des Devel Ther"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis","volume":"133","author":"Samarasekera EJ","year":"2013","unstructured":"Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013, 133:2340-6. 10.1038\/jid.2013.149","journal-title":"J Invest Dermatol"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study","volume":"136","author":"Lerman JB","year":"2017","unstructured":"Lerman JB, Joshi AA, Chaturvedi A, et al.. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation. 2017, 136:263-76. 10.1161\/CIRCULATIONAHA.116.026859","journal-title":"Circulation"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.04.25337310","article-title":"Obesity-associated genetic variants and AMPK signaling in cardiovascular \r\ndisease: a systematic review of mechanisms and clinical implications","author":"Siddiqui I","year":"2025","unstructured":"Siddiqui I, Khan NA, Haider Z. Obesity-associated genetic variants and AMPK signaling in cardiovascular \r\ndisease: a systematic review of mechanisms and clinical implications. medRxiv. 2025, 10.1101\/2025.10.04.25337310","journal-title":"medRxiv"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020792","article-title":"Vascular cell adhesion molecule 1 and E-selectin as potential cardiovascular risk biomarkers in psoriasis","volume":"26","author":"Macho\u0144 NJ","year":"2025","unstructured":"Macho\u0144 NJ, Zdanowska N, Klimek-Trojan P, Owczarczyk-Saczonek A. Vascular cell adhesion molecule 1 and E-selectin as potential cardiovascular risk biomarkers in psoriasis. Int J Mol Sci. 2025, 26:792. 10.3390\/ijms26020792","journal-title":"Int J Mol Sci"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041708","article-title":"The interplay between immunity, inflammation and endothelial dysfunction","volume":"26","author":"Chee YJ","year":"2025","unstructured":"Chee YJ, Dalan R, Cheung C. The interplay between immunity, inflammation and endothelial dysfunction. Int J Mol Sci. 2025, 26:1708. 10.3390\/ijms26041708","journal-title":"Int J Mol Sci"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.12.001","article-title":"Peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) acts as regulator of metabolism linked to multiple cellular functions","volume":"125","author":"Wagner KD","year":"2010","unstructured":"Wagner KD, Wagner N. Peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2010, 125:423-35. 10.1016\/j.pharmthera.2009.12.001","journal-title":"Pharmacol Ther"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00148.2009","article-title":"Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production","volume":"297","author":"Kleinhenz JM","year":"2009","unstructured":"Kleinhenz JM, Kleinhenz DJ, You S, et al.. Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol. 2009, 297:H1647-54. 10.1152\/ajpheart.00148.2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411662","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment","volume":"24","author":"Lee BW","year":"2023","unstructured":"Lee BW, Moon SJ. Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment. Int J Mol Sci. 2023, 24:11662. 10.3390\/ijms241411662","journal-title":"Int J Mol Sci"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.672515","article-title":"From bed to bench and back: TNF-\u03b1, IL-23\/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis","volume":"12","author":"Silvagni E","year":"2021","unstructured":"Silvagni E, Missiroli S, Perrone M, et al.. From bed to bench and back: TNF-\u03b1, IL-23\/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis. Front Pharmacol. 2021, 12:672515. 10.3389\/fphar.2021.672515","journal-title":"Front Pharmacol"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.5","article-title":"Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial","volume":"145","author":"Mittal R","year":"2009","unstructured":"Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009, 145:387-93. 10.1001\/archdermatol.2009.5","journal-title":"Arch Dermatol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.932324","article-title":"Clinical effects of \"pioglitazone\", an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1","volume":"26","author":"Hafez VG","year":"2015","unstructured":"Hafez VG, Bosseila M, Abdel Halim MR, Shaker OG, Kamal M, Kareem HS. Clinical effects of \"pioglitazone\", an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. J Dermatolog Treat. 2015, 26:208-14. 10.3109\/09546634.2014.932324","journal-title":"J Dermatolog Treat"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_88_19","article-title":"The evaluation of efficacy and safety of methotrexate and pioglitazone in psoriasis patients: a randomized, open-labeled, active-controlled clinical trial","volume":"52","author":"Abidi A","year":"2020","unstructured":"Abidi A, Rizvi DA, Saxena K, Chaudhary S, Ahmad A. The evaluation of efficacy and safety of methotrexate and pioglitazone in psoriasis patients: a randomized, open-labeled, active-controlled clinical trial. Indian J Pharmacol. 2020, 52:16-22. 10.4103\/ijp.IJP_88_19","journal-title":"Indian J Pharmacol"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2005.04434.x","article-title":"Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient","volume":"4","author":"Pershadsingh HA","year":"2005","unstructured":"Pershadsingh HA, Benson SC, Ellis CN. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed. 2005, 4:386-90. 10.1111\/j.1540-9740.2005.04434.x","journal-title":"Skinmed"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-012-0001-z","article-title":"Pioglitazone in clinical practice: where are we now?","volume":"3","author":"Govindan J","year":"2012","unstructured":"Govindan J, Evans M. Pioglitazone in clinical practice: where are we now?. Diabetes Ther. 2012, 3:1-8. 10.1007\/s13300-012-0001-z","journal-title":"Diabetes Ther"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff AM","year":"2007","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007, 298:1180-8. 10.1001\/jama.298.10.1180","journal-title":"JAMA"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1610552","article-title":"Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Chang G","year":"2020","unstructured":"Chang G, Wang J, Song J, Zhang Z, Zhang L. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2020, 31:680-6. 10.1080\/09546634.2019.1610552","journal-title":"J Dermatolog Treat"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1357309","article-title":"Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials","volume":"16","author":"Azhari HF","year":"2025","unstructured":"Azhari HF, Dawson J. Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials. Front Pharmacol. 2025, 16:1357309. 10.3389\/fphar.2025.1357309","journal-title":"Front Pharmacol"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels B","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998, 98:2088-93. 10.1161\/01.cir.98.19.2088","journal-title":"Circulation"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15107","article-title":"Nuclear receptors for epidermal lipid barrier: advances in mechanisms and applications","volume":"33","author":"Yin X","year":"2024","unstructured":"Yin X, Yan Y, Li J, et al.. Nuclear receptors for epidermal lipid barrier: advances in mechanisms and applications. Exp Dermatol. 2024, 33:e15107. 10.1111\/exd.15107","journal-title":"Exp Dermatol"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.05.020","article-title":"Improvement of psoriatic arthritis by pioglitazone treatment in a type 2 diabetic patient","volume":"90","author":"Takahara M","year":"2010","unstructured":"Takahara M, Shiraiwa T, Kaneto H, et al.. Improvement of psoriatic arthritis by pioglitazone treatment in a type 2 diabetic patient. Diabetes Res Clin Pract. 2010, 90:e9-e10. 10.1016\/j.diabres.2010.05.020","journal-title":"Diabetes Res Clin Pract"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2011-100388","article-title":"Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis","volume":"17","author":"Malhotra A","year":"2012","unstructured":"Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med. 2012, 17:171-6. 10.1136\/ebmed-2011-100388","journal-title":"Evid Based Med"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111083","article-title":"Lipid nanoparticulate drug delivery systems: recent advances in the treatment of skin disorders","volume":"14","author":"Stefanov SR","year":"2021","unstructured":"Stefanov SR, Andonova VY. Lipid nanoparticulate drug delivery systems: recent advances in the treatment of skin disorders. Pharmaceuticals (Basel). 2021, 14:1083. 10.3390\/ph14111083","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1039\/d1ra06087b","article-title":"Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects","volume":"11","author":"Mohd Nordin UU","year":"2021","unstructured":"Mohd Nordin UU, Ahmad N, Salim N, Mohd Yusof NS. Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects. RSC Adv. 2021, 11:29080-101. 10.1039\/d1ra06087b","journal-title":"RSC Adv"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79225-1","article-title":"Luliconazole-loaded nanostructured lipid carrier: formulation, characterization, and in vitro antifungal evaluation against a panel of resistant fungal strains","volume":"14","author":"Nosratabadi M","year":"2024","unstructured":"Nosratabadi M, Rahimnia SM, Barogh RE, et al.. Luliconazole-loaded nanostructured lipid carrier: formulation, characterization, and in vitro antifungal evaluation against a panel of resistant fungal strains. Sci Rep. 2024, 14:30708. 10.1038\/s41598-024-79225-1","journal-title":"Sci Rep"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202X.2003.22111.x","article-title":"Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes","volume":"122","author":"Bhagavathula N","year":"2004","unstructured":"Bhagavathula N, Nerusu KC, Lal A, et al.. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol. 2004, 122:130-9. 10.1046\/j.0022-202X.2003.22111.x","journal-title":"J Invest Dermatol"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1177\/20417314221085390","article-title":"Application of microneedle patches for drug delivery; doorstep to novel therapies","volume":"13","author":"Nazary Abrbekoh F","year":"2022","unstructured":"Nazary Abrbekoh F, Salimi L, Saghati S, et al.. Application of microneedle patches for drug delivery; doorstep to novel therapies. J Tissue Eng. 2022, 13:20417314221085390. 10.1177\/20417314221085390","journal-title":"J Tissue Eng"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.3390\/molecules191220780","article-title":"Prodrug strategies for enhancing the percutaneous absorption of drugs","volume":"19","author":"N'Da DD","year":"2014","unstructured":"N'Da DD. Prodrug strategies for enhancing the percutaneous absorption of drugs. Molecules. 2014, 19:20780-807. 10.3390\/molecules191220780","journal-title":"Molecules"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/454054-peroxisome-proliferator-activated-receptors-ppars-in-psoriasis-metabolic-intersections-molecular-mechanisms-and-potential-treatments","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:32:10Z","timestamp":1772515930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/454054-peroxisome-proliferator-activated-receptors-ppars-in-psoriasis-metabolic-intersections-molecular-mechanisms-and-potential-treatments"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":145,"URL":"https:\/\/doi.org\/10.7759\/cureus.104583","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}